Sports and burn therapies firm Vericel Q3 revenue beats estimates

Vericel

06/11/2025 13:03

Overview

Vericel Q3 revenue of $67.5 mln beats analyst expectations

MACI revenue grows 25% to $55.7 mln, driving overall revenue growth

Net income for Q3 at $5.1 mln, compared to a loss last year

Outlook

Vericel projects full-year revenue of $272 to $276 mln

Company reaffirms MACI revenue growth in low 20% range

Vericel maintains full-year gross margin guidance at 74%

MACI sales force expansion on track for completion in Q4, supporting future growth

Result Drivers

MACI REVENUE GROWTH - MACI revenue increased by 25% to $55.7 mln, contributing significantly to overall revenue growth

NEXOBRID REVENUE GROWTH - NexoBrid revenue grew 38% year-over-year and 26% quarter-over-quarter, marking a record quarter

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$67.50 mln
$64.60 mln (8 Analysts)
Q3 EPS
$0.10
Q3 Net Income
$5.07 mln
Q3 Adjusted EBITDA
$17 mln
Q3 Gross Margin
73.50%
Q3 Adjusted EBITDA Margin
25.00%
Q3 Gross Profit
$49.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vericel Corp is $55.00, about 32.4% above its November 5 closing price of $37.20

The stock recently traded at 72 times the next 12-month earnings vs. a P/E of 70 three months ago

Press Release: ID:nGNX5tDGzT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)